Dynamics in maturation of SARS-CoV-2 RBD-specific IgG antibody avidity depending on immunization timeframe and type

封面

如何引用文章

全文:

详细

The aim is to examine dynamics of avidity maturation of IgG antibodies against SARS-CoV-2 RBD depending on the type of immunization (vaccination or infection), as well as on the duration and frequency of immunization. Materials and methods. The study was performed on two sample cohorts collected at two time points during COVID-19 pandemic. The first cohort (group No. 1) consisted of 87 samples of blood sera obtained from COVID-19 convalescents in the period from March to September 2020. The second cohort included 204 samples obtained in September 2021 from two patient groups. Group No. 2 (n = 64) — patients immunized with a full course of Gam-Covid-Vac, group No. 3 (n = 140) — COVID-19 convalescent patients and subjects vaccinated with Gam-Covid-Vac (“hybrid immunity”). Results and conclusion. The dynamics of avidity maturation for SARS-CoV-2 RBD IgG antibodies depending on the method and frequency of immunization, showed that the most effective immunity was formed in COVID-19 convalescent patients and subjects vaccinated with a full course of Gam-Covid-Vac. The “hybrid” immunity showed not only a significantly higher (compared with groups No. 1 and No. 2) level of IgG antibodies (median 228 BAU/ml vs 75 or 119 BAU/ml, p < 0.001), but also a higher level of avidity (IA 90.5% vs 54.5 and 76.6, respectively, p < 0.001, 4M urea). In the test for assessing the avidity index with the denaturing agent 8M urea in patients with “hybrid immunity”, the median level of IA was 25% versus 14.8% and 16% in COVID-19 convalescents and vaccinated subjects (p < 0.001), only in 8 patients IA was higher than 50%. While comparing a single infection of COVID-19 with a full course of Gam-Covid-Vac, it was shown that vaccination leads to higher IgG levels (median values in groups 119 and 75 BAU/ml, p < 0.001) and to a higher avidity index (median 76.6% vs 54.5%). Thus, the more rapid induction of high-avidity antibodies was in vaccinated individuals at early stages of immunization (up to 4 months), during the period when IgG avidity maturation has not yet been completed. Our results showed that during this period vaccination leads to production of antibodies with avidity index at median level of 82% versus 36% in COVID-19 convalescents at similar time point.

作者简介

Alexandra Kudryashova

Mechnikov Research Institute of Vaccines and Sera

编辑信件的主要联系方式.
Email: 2238250@rambler.ru

Researcher, Laboratory of Medical Biotechnology

俄罗斯联邦, Moscow

Victor Manuylov

Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of health of Russian Federation

Email: 2238250@rambler.ru

PhD (Biology), Senior Researcher, Laboratory of Translational Biomedicine

俄罗斯联邦, Moscow

Alyona Murzina

Mechnikov Research Institute of Vaccines and Sera

Email: 2238250@rambler.ru

Junior Researcher, Laboratory of the Epidemiological Analysis and Monitoring of Infectious Diseases

俄罗斯联邦, Moscow

Alla Kaira

Mechnikov Research Institute of Vaccines and Sera

Email: 2238250@rambler.ru

DSc (Medicine), Head of the Laboratory of Epidemiologic Analysis and Monitoring of Infectious Diseases

俄罗斯联邦, Moscow

Olga Borisova

Mechnikov Research Institute of Vaccines and Sera

Email: 2238250@rambler.ru

PhD (Chemistry), Head of the Laboratory of Medical Biotechnology

俄罗斯联邦, Moscow

参考

  1. Abdullahi Nasir I., Babayo A., Shehu M.S. Clinical significance of IgG avidity testing and other considerations in the diagnosis of congenital cytomegalovirus infection: a review update. Med. Sci. (Basel), 2016, vol. 4, no. 1: 5. doi: 10.3390/medsci4010005
  2. Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int. J. Infect. Dis., 2021, no. 106, pp. 61–64. doi: 10.1016/j.ijid.2021.01.061
  3. Benner S.E., Patel E.U., Laeyendecker O., Pekosz A., Littlefield K., Eby Y., Fernandez R.E., Miller J., Kirby C.S., Keruly M., Klock E., Baker O.R., Schmidt H.A., Shrestha R., Burgess I., Bonny T.S., Clarke W., Caturegli P., Sullivan D., Shoham S., Quinn T.C., Bloch E.M., Casadevall A., Tobian A.A.R., Redd A.D. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J. Infect. Dis., vol. 222, no. 12, pp. 1974–1984. doi: 10.1093/infdis/jiaa581
  4. Chan K.H., Sonnenberg K., Niedrig M., Lam S.Y., Pang C.M., Chan K.M., Ma S.K., Seto W.H., Peiris J.S. Use of antibody avidity assays for diagnosis of severe acute respiratory syndrome coronavirus infection. Clin. Vaccine Immunol., 2007, vol. 14, no. 11, pp. 1433–1436. doi: 10.1128/CVI.00056-07
  5. Chan P.K., Lim P.L., Liu E.Y., Cheung J.L., Leung D.T., Sung J.J. Antibody avidity maturation during severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis., 2005, vol. 192, no. 1, pp. 166–169. doi: 10.1086/430615
  6. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., Diaz L., Trento A., Chang H.Y., Mitzner W., Ravetch J., Melero J.A., Irusta P.M., Polack F.P. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med., 2009, vol. 15, no. 1, pp. 34–41. doi: 10.1099/jgv.0.001439
  7. Ding Y.X., Mao N.Y., Zhang Y., Lei Y., Gao Z.G., Xu W.B., Zhang Y. Measles virus IgG avidity assay for use in identification of measles vaccine failures in Tianjin, China. Biomed. Environ. Sci., 2019, vol., 32, no. 11, pp. 804–811. doi: 10.3967/bes2019.102
  8. Dörner T., Radbruch A. Antibodies and B cell memory in viral immunity. Immunity, 2007, vol. 27, no. 3, pp. 384–392. doi: 10.1016/ j.immuni.2007.09.002
  9. Hedman K., Seppälä I. Recent rubella virus infection indicated by a low avidity of specific IgG. J. Clin. Immunol., 1988, vol. 8, no. 3, pp. 214–221. doi: 10.1007/BF00917569
  10. Kaneko M., Ohhashi M., Minematsu T., Muraoka J., Kusumoto K., Sameshima H. Maternal immunoglobulin G avidity as a diagnostic tool to identify pregnant women at risk of congenital cytomegalovirus infection. J. Infect. Chemother., 2017, vol. 2, no. 3, pp. 173–176. doi: 10.1016/j.jiac.2016.12.001
  11. Klein S.L., Pekosz A., Park H.S., Ursin R.L., Shapiro J.R., Benner S.E., Littlefield K., Kumar S., Naik H.M., Betenbaugh M.J., Shrestha R., Wu A.A., Hughes R.M., Burgess I., Caturegli P., Laeyendecker O., Quinn T.C., Sullivan D., Shoham S., Redd A.D., Bloch E.M., Casadevall A., Tobian A.A. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J. Clin. Invest., 2020, vol. 130, no. 11, pp. 6141–6150. doi: 10.1172/JCI142004
  12. Leruez-Ville M., Ville Y. Is it time for routine prenatal serological screening for congenital cytomegalovirus? Prenat. Diagn., 2020, vol. 40, no. 13, pp. 1671–1680. doi: 10.1002/pd.5757
  13. Liu T., Hsiung J., Zha S., Kost J., Sreedhar D., Hanson C.V., Olson K., Keare D., Chang S.T., Bliden K.P., Gurbel P.A., Tantry U.S., Roche J., Press C., Boggs J., Rodriguez-Soto J.P., Montoya J.G., Tang M., Dai H. Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. Nat. Biomed. Eng., 2020, vol. 4, no. 12, pp. 1188–1196. doi: 10.1038/s41551-020-00642-4
  14. Luo Y.R., Chakraborty I., Yun C., Wu A. H B, Lynch K.L. Kinetics of SARS-CoV-2 antibody avidity maturation and association with disease severity. Clin. Infect. Dis., 2020, vol. 73, no. 9, pp. e3095–e3097. doi: 10.1093/cid/ciaa1389
  15. Manuylov V., Burgasova O., Borisova O., Smetanina S., Vasina D., Grigoriev I., Kudryashova A., Semashko M., Cherepovich B., Kharchenko O., Kleymenov D., Mazunina E., Tkachuk A., Gushchin V. Avidity of IgG to SARS-CoV-2 RBD as a prognostic factor for the severity of COVID-19 reinfection. Viruses, 2022, vol. 14, no. 3: 617. doi: 10.3390/v14030617
  16. Mattiuzzo G., Bentley E.M., Hassall M., Routley S., Richardson S., Bernasconi V., Kristiansen P., Harvala H., David Roberts D., Semple M.G., Turtle L.C.W., Openshaw P.J.M., Baillie K., Nissen-Meyer L.S.H., Brantsæter A.B., Baxendale H., Atkinson E., Rigsby P., Padley D., Almond N., Rose N.J. Establishment of the WHO International standard and reference panel for anti-SARS-CoV-2 antibody. Expert Committee on Biological Standartization, Geneva, 9–10 December 2020. doi: WHO/BS/2020.2403E
  17. Puschnik A., Lau L., Cromwell E.A., Balmaseda A., Zompi S., Harris E. Correlation between Dengue-specific neutralizing antibodies and serum avidity in primary and secondary Dengue virus 3 natural infections in humans. PLoS Negl Trop. Dis., 2013, vol. 7, no. 6: e2274. doi: 10.1371/journal.pntd.0002274
  18. Revello M.G., Zavattoni M., Furione M., Lilleri D., Gorini G., Gerna G. Diagnosis and outcome of preconceptional and periconceptional primary human cytomegalovirus infections. J. Infect. Dis., 2002, vol. 186, no. 4, pp. 553–557. doi: 10.1086/341831
  19. Struck F., Schreiner P., Staschik E., Wochinz-Richter K., Schulz S., Soutschek E., Motz M., Bauer G. Vaccination versus infection with SARS-CoV-2: establishment of a high avidity IgG response versus incomplete avidity maturation. J. Med. Virol., 2021, vol. 93, no. 12, pp. 6765–6777. doi: 10.1002/jmv.27270
  20. Struck F., Schreiner P., Staschik E., Wochinz-Richter K., Schulz S., Soutschek E., Motz M., Bauer G. Incomplete IgG avidity maturation after seasonal coronavirus infections. J. Med. Virol., 2021, vol. 94, no. 1, pp. 186–196. doi: 10.1002/jmv.27291
  21. Vauloup-Fellous C., Grangeot-Keros L. Humoral immune response after primary rubella virus infection and after vaccination. Clin. Vaccine Immunol., 2007, vol. 14, no. 5, pp. 5644–5647. doi: 10.1128/CVI.00032-07
  22. Wratil P.R., Stern M., Priller A., Willmann A., Almanzar G., Vogel E., Feuerherd M., Cheng C.C., Yazici S., Christa C., Jeske S., Lupoli G., Vogt T., Albanese M., Mejías-Pérez E., Bauernfried S., Graf N., Mijocevic H., Vu M., Tinnefeld K., Wettengel J., Hoffmann D., Muenchhoff M., Daechert C., Mairhofer H., Krebs S., Fingerle V., Graf A., Steininger P., Blum H., Hornung V., Liebl B., Überla K., Prelog M., Knolle P., Keppler O.T., Protzer U. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat. Med., 2022, vol. 28, no. 3, pp. 496–503. doi: 10.1038/s41591-022-01715-4

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Kudryashova A.M., Manuylov V.A., Murzina A.A., Kaira A.N., Borisova O.V., 2023

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##